To evaluate disease-free survival (DFS), we utilized data from TCGA database and conducted a DFS analysis, which revealed that prostate cancer patients with lower HSPB6 expression had poorer disease-free survival rates (Fig. 2F). This evidence concerns the gene HSPB6 and Familial prostate cancer.